What should be the optimal cut-off of serum 1,3-β-d-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies?

Abstract Background: The detection of 1,3-β-d-glucan (BDG), a cell wall component of several medically important fungi, is a promising tool for the diagnosis of invasive pulmonary aspergillosis. The aim of this study was to evaluate the diagnostic accuracy of the BDG test in invasive pulmonary aspergillosis (IPA) by focusing on the optimal cut-off value. Methods: The records of the Infection Control Committee were reviewed to identify patients with haematological malignancies and stem cell transplantation who had at least 1 BDG (Fungitell kit) measurement during the period January 2008 through April 2011. The European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) criteria (independent of BDG results) were used to categorize the patients with IPA. Patients with possible IPA were not included in the study. Results: A total of 128 patients (50 with proven or probable IPA) were included in the study. At the manufacturer's recommended cut-off value of 80 pg/ml, the sensitivity of BDG was 66% (95% CI 51.2–78.7), specificity 75.6% (95% CI 64.6–84.5), positive predictive value (PPV) 63.4%, and negative predictive value (NPV) 77.6%. A receiver operating characteristic (ROC) curve was constructed to define the optimum serum BDG cut-off for the diagnosis of IPA. At a cut-off value of 181 pg/ml, the sensitivity was 52% (95% CI 37.4–66.3), specificity 94.8% (95% CI 87.4–98.6), PPV 86.7%, and NPV 75.5%. Conclusions: Although higher cut-off levels increased the specificity of the BDG test, sensitivity decreased to an unacceptable level; the commercially recommended cut-off value appears to be appropriate for screening purposes.

[1]  M. Falagas,et al.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  I. Kocmanova,et al.  Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. , 2010, Journal of medical microbiology.

[3]  J. Perfect,et al.  The (1,3)β-d-Glucan Test as an Aid to Early Diagnosis of Invasive Fungal Infections following Lung Transplantation , 2010, Journal of Clinical Microbiology.

[4]  Kenichi Kato,et al.  Evaluation of the clinical cutoff level of serum (1 → 3)-β-d-glucan in patients with connective tissue diseases complicated by deep fungal infections , 2010, Modern rheumatology.

[5]  A. Koç,et al.  The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-d-glucan in patients without risk factors for invasive fungal infections , 2010, Infection.

[6]  S. Koo,et al.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Moore,et al.  Identification of airborne bacterial and fungal species in the clinical microbiology laboratory of a university teaching hospital employing ribosomal DNA (rDNA) PCR and gene sequencing techniques , 2009, International journal of environmental health research.

[8]  S. Koo,et al.  Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. , 2009, Medical mycology.

[9]  D. Kontoyiannis,et al.  Utility of Galactomannan Enzyme Immunoassay and (1,3) β-d-Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for Aspergillus fumigatus Infection in Hematologic Malignancy Patients , 2008, Journal of Clinical Microbiology.

[10]  C. Viscoli,et al.  Invasive aspergillosis: diagnosis, prophylaxis and treatment , 2008, Current opinion in hematology.

[11]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Vesper,et al.  Use of (1-3)-beta-d-glucan concentrations in dust as a surrogate method for estimating specific fungal exposures. , 2008, Indoor air.

[13]  T. Calandra,et al.  1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Ranque,et al.  Contribution of the (1→3)-β-d-Glucan Assay for Diagnosis of Invasive Fungal Infections , 2007, Journal of Clinical Microbiology.

[15]  A. Kedzierska,et al.  Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1→3)-β-D-glucan antigens , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[16]  M. Finkelman,et al.  Reactivity of (1→3)-β-d-Glucan Assay with Commonly Used Intravenous Antimicrobials , 2006, Antimicrobial Agents and Chemotherapy.

[17]  Amy M. Kelaher Two Non-invasive Diagnostic Tools for Invasive Aspergilosis: (1-3)-β-D-Glucan and the Galactomannan Assay , 2006, American Society for Clinical Laboratory Science.

[18]  M. Mcginnis,et al.  Differences in beta-glucan levels in culture supernatants of a variety of fungi. , 2006, Medical mycology.

[19]  M. Finkelman,et al.  Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. , 2006, Antimicrobial agents and chemotherapy.

[20]  B. Alexander,et al.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Pontón,et al.  Contribution of (1→3)-β-d-Glucan Chromogenic Assay to Diagnosis and Therapeutic Monitoring of Invasive Aspergillosis in Neutropenic Adult Patients: a Comparison with Serial Screening for Circulating Galactomannan , 2005, Journal of Clinical Microbiology.

[22]  E. Estey,et al.  β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .